Tech Company Financing Transactions
eFFECTOR Therapeutics Funding Round
eFFECTOR Therapeutics, based in San Diego, secured $16 million from Sectoral Asset Management and private investors.
Transaction Overview
Company Name
Announced On
2/19/2016
Transaction Type
Venture Equity
Amount
$16,000,000
Round
Series B
Investors
Sectoral Asset Management (Maha Katabi)
Proceeds Purpose
These developments further position eFFECTOR to pursue comprehensive clinical development of its lead product candidate, eFT508, a potent, highly selective, and orally bioavailable MNK1 and MNK2 inhibitor, across multiple tumor types. The funds will also be used to advance the company's discovery pipeline addressing additional targets.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
11180 Roselle St.
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Effector Therapeutics is an early-stage company focused on the discovery and development of small molecule cancer therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steve Worland
Chief Financial Officer
Alana McNulty
VP - R & D
Siegfried Reich
Browse more venture capital transactions:
Prev: 2/19/2016: Pliant Therapeutics venture capital transaction
Next: 2/19/2016: Arteris venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. All VC database entries on this site are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs